Transforming Niclosamide through Nanotechnology: A Promising Approach for Long COVID Management DOI Creative Commons
N. Sanoj Rejinold, Goeun Choi, Geun‐woo Jin

et al.

Small, Journal Year: 2025, Volume and Issue: unknown

Published: May 19, 2025

Abstract Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has infected over 770 million people worldwide. The long‐term effects of COVID‐19 and their management have become important issues. Accumulating evidence indicates that post‐COVID‐19 syndrome, also known as long COVID, is not limited to symptoms but affects a wide range systems, including neurological, cardiovascular, gastrointestinal, musculoskeletal, reproductive systems etc. social economic losses associated with these are estimated reach 3·7 trillion dollars in the United States alone. However, no treatment for COVID been developed. Herein, literature on comprehensively reviewed examine underlying causes. Additionally, supporting efficacy nanoengineered niclosamide presented, given its ability counteract Niclosamide already Food Drug Administration (FDA)‐approved, one viable candidate clinical trials COVID.

Language: Английский

Transforming Niclosamide through Nanotechnology: A Promising Approach for Long COVID Management DOI Creative Commons
N. Sanoj Rejinold, Goeun Choi, Geun‐woo Jin

et al.

Small, Journal Year: 2025, Volume and Issue: unknown

Published: May 19, 2025

Abstract Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has infected over 770 million people worldwide. The long‐term effects of COVID‐19 and their management have become important issues. Accumulating evidence indicates that post‐COVID‐19 syndrome, also known as long COVID, is not limited to symptoms but affects a wide range systems, including neurological, cardiovascular, gastrointestinal, musculoskeletal, reproductive systems etc. social economic losses associated with these are estimated reach 3·7 trillion dollars in the United States alone. However, no treatment for COVID been developed. Herein, literature on comprehensively reviewed examine underlying causes. Additionally, supporting efficacy nanoengineered niclosamide presented, given its ability counteract Niclosamide already Food Drug Administration (FDA)‐approved, one viable candidate clinical trials COVID.

Language: Английский

Citations

0